Generated: May 24, 2017
|Title:||Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate|
|Abstract:||A method of reducing mortality associated with chronic congestive heart failure in a patient with impaired cardiac function and concomitant reduced exercise tolerance, comprising the oral administration to said patient in need of the same of a combination of (a) between about 75 and about 300 milligrams of hydralazine, per day and (b) between about 40 and about 160 milligrams of isosorbide dinitrate, per day.|
|Inventor(s):||Cohn; Jay N. (Minneapolis, MN)|
1. A method of reducing the incidence of mortality associated with chronic congestive heart failure in a patient with impaired cardiac function and concomitant reduced
exercise tolerance, comprising the oral administration to said patient in need of the same of a combination of
(a) between about 75 and about 300 milligrams of hydralazine, or a pharmaceutically acceptable acid addition salt thereof, per day, and
(b) between about 40 and about 160 milligrams of isosorbide dinitrate, per day.
2. A method according to claim 1, wherein said patient is further treated orally with digoxin in an amount sufficient to achieve in said patient a blood serum concentration of digoxin of at least about 0.7 nanograms per milliliter and an effective edema managing amount of a pharmaceutically acceptable diuretic selected from the group consisting of thiazides, ethacrynic acid, furosemide, spironalactone and triamterene.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.